Check Back Soon For Pipeline Illustration

Enlyton’s pipeline focuses on antibody-directed technologies.

Human safety and proof-of-concept for previous versions of ATA-1  have already been proven in multiple human clinical trials.

ATA-1 is currently positioned for a Phase I-II clinical trial pending cGMP antibody production.

Additional product uses for the antibody component of ATA-1 include targeted drug delivery and optical detection applications.